摘要
目的研究对慢阻肺患者实施噻托溴铵与沙美特罗替卡松联合治疗的效果。方法方便选取该院2017年4月—2018年4月期间收入的84例慢阻肺患者纳入该次实验,根据病历单双号分为单药组42例(噻托溴铵治疗)和联合组42例(沙美特罗替卡松+噻托溴铵治疗),统计并比较两组治疗总有效率、肺功能、不良反应情况。结果联合组治疗总有效率97.62%高于单药组的80.95%,差异有统计学意义(χ2=4.480,P=0.034);治疗前两组FEV1、FVC以及PEF水平比较,差异无统计学意义(P>0.05);治疗后两组FEV1、FVC以及PEF水平均升高,但联合组比单药组水平更高,差异有统计学意义(t=2.903、4.152、2.439,P<0.05);联合组药物不良反应发生率7.14%(3/42)与单药组的4.76%(2/42)比较,差异无统计学意义(χ2=0.506,P=0.477)。结论对慢阻肺患者实施噻托溴铵与沙美特罗替卡松联合治疗,可以提高治疗总有效率,利于提升患者肺功能,不会增加药物不良反应,治疗期间较为安全。
Objective To study the effect of combined treatment of tiotropium bromide and salmeterol on patients with chronic obstructive pulmonary disease.Methods A total of 84 patients with chronic obstructive pulmonary disease who were admitted in the hospital from April 2017 to April 2018 were conveniently selected in this experiment.According to the single and double numbers of the medical records,they were divided into a single-drug group of 42 patients(treated with tiotropium bromide)and a combination group of 42 cases(treatment with salmeterol and tiotropium bromide),the total effective rate,lung function,and adverse reactions of the two groups were counted and compared.Results The total effective rate of treatment in the combination group was 97.62%higher than that of the single-agent group 80.95%,the difference was statistically significant(χ2=4.480,P=0.034);there was no statistically significant difference in the levels of FEV1,FVC and PEF between the two groups before treatment(P>0.05);FEV1,FVC and PEF levels increased in the two groups after treatment,but the combined group was higher than the single-drug group,the difference was statistically significant(t=2.903,4.152,2.439,P<0.05);the adverse drug reaction rate of the combination group was 7.14%(3/42)compared with 4.76%(2/42)of the single-drug group,the difference was not statistically significant(χ2=0.506,P=0.477).Conclusion The combined treatment of tiotropium bromide and salmeterol ticasone in patients with COPD can improve the total effective rate of treatment,help improve the patient's lung function,and will not increase adverse drug reactions.The treatment period is relatively safe.
作者
刘敏
余春晓
化静
张建红
LIU Min;YU Chun-xiao;HUA Jing;ZHANG Jian-hong(Beijing Jingmei Group General Hospital,Beijing,102300 China)
出处
《中外医疗》
2020年第28期91-93,共3页
China & Foreign Medical Treatment
关键词
慢阻肺
噻托溴铵
沙美特罗替卡松
疗效
安全性
Chronic obstructive pulmonary
Tiotropium bromide
Salmeterol ticasone
Efficacy
Safety
